BLASINGLE-DOSEVIAL
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
6/8 — Strong
KANJINTI (trastuzumab-anns) by Amgen is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KANJINTI (trastuzumab-anns) is a monoclonal antibody biosimilar that targets HER2/neu receptors on cancer cells. It is used to treat HER2-positive breast cancer and gastric cancer by blocking HER2-driven growth signals. This Amgen-sponsored biosimilar provides an alternative to reference trastuzumab (Herceptin) with equivalent efficacy and safety.
$4.0MPart D
PeakProduct is in peak lifecycle stage with modest Part D penetration ($4M spending, 875 claims in 2023), indicating established market position but limited growth trajectory relative to larger competitors.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on KANJINTI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.